Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVRx closes $65m record:

This article was originally published in Clinica

Executive Summary

Hypertension treatment specialist CVRx has received $65m in a fourth round financing led by Johnson & Johnson's venture capital arm, J&J Development (JJD). As part of the financing, Brad Vale, vice president of JJD, has joined Maple Grove, Minnesota-based CVRx's board of directors. The round saw new investor BBT Fund LP combine with existing shareholders New Enterprise, Thomas Weisel, InterWest, ABS, Frazier Healthcare and SightLine to bring the overall financing to in excess of $125m. CVRx will use the funds to advance the current pivotal clinical trials of its Rheos Baroflex hypertension therapy system, which it claims is the only implantable device designed to control hypertension.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel